Abstract 101P
Background
The proven success of combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy in estrogen receptor-positive (ER+) metastatic breast cancer has prompted evaluation of this therapeutic approach in patients with early-stage disease. Notably, the CDK4/6i abemaciclib and ribociclib, but not palbociclib, improved invasive disease-free survival in the adjuvant setting in clinical trials. These data suggest that complex assessment of breast tumor genomic, clinical and pathological characteristics, and CDK4/6i efficacy and toxicity profiles, will be required for a better refinement of indication for specific CDK4/6i in the early-stage setting. In the present study, we aimed to identify and characterize the early breast cancer patient population that will benefit the most from each CDK4/6i by using patient-derived breast cancer organoids.
Methods
We developed a repository of patient-derived organoids (PDOs) from ER+ primary breast tumor resections. RNA, DNA, and protein were purified from PDOs and paired fresh frozen tissue, for validation of organoids characteristics compared to the original tumor. To fully characterize our PDOs, we performed RNA sequencing (RNAseq), single nucleotide polymorphism/copy number variation (SNP/CNV) array, live-cell imaging, quantitative real-time PCR, and drug testing. Efficacy of CDK4/6i on selected PDOs was evaluated by viability and cytotoxicity assays, and gene expression profile in sensitive vs. resistant PDOs was compared by RNAseq.
Results
We found that various PDOs retained the main alterations of the original tumor, by SNP/CNV arrays. Furthermore, we were able to rank the organoids based on the response (IC50) to abemaciclib. By RNAseq and RT-qPCR we identified specific genes that might be linked with differential responses to CDK4/6i. Among these, we found concomitant CDK6 overexpression and, surprisingly, cyclin D1 downregulation in PDOs with higher IC50 towards CDK4/6i in both innate and acquired resistance models.
Conclusions
Our data suggest that high-CDK6 and low-cyclin D1 expression might be a biomarker for selection of patients with poor response to CDK4/6i abemaciclib in the adjuvant setting.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Ethics Committee of the Region of Southern Denmark and Copenhagen and Frederiksberg Counties; Danish Data Protection Agency and the Danish Breast Cancer Cooperative Group.
Funding
Danish Cancer Society; Sygeforsikring Danmark; Danmarks 3R-Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract